Mon, Apr 21, 2014, 10:19 AM EDT - U.S. Markets close in 5 hrs 41 mins

Recent

% | $
Quotes you view appear here for quick access.

Synthetic Biologics Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • buckfarmer777 buckfarmer777 Jan 9, 2010 9:46 AM Flag

    ANY stock.............period

    Positive and more importantly, REALISTIC! Good luck guys!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Oh, since you guys obviously like biotech. Have a look a Clinuvel Pharmaceuticals. The reported the following Phase III results on December 21st and no run-up yet? Why not? Because it is an Australian company you think?

      Preliminary Results
      An interim analysis of data from the first 4 months of treatment (March-October) in this 12 month trial was undertaken. The study employed a crossover comparison of afamelanotide (3 doses) and placebo (3 doses) in 100 patients. At dose intervals of 2 months, each patient received a single dose of either treatment.

      Analysis of 2 treatment arms showed an overall reduction in the average number of phototoxic reactions. Thirty five patients with severe and/or moderate pain reported the greatest reduction in mean number of reactions (p=0.03, 95% CI). Analysis of pain severity was positively correlated with treatment, indicating that patient pain scores differed significantly between treatment groups (p=0.006, 95% CI).

      Although the analysis of quality of life data is not yet complete, all 8 physicians involved in this trial reported a dramatic improvement in the patients’ ability to engage in outdoors activities. Safety reports from all academic centres are excellent to date.

      This study will be completed by the end of December 2009, after which a full analysis of data will follow.

 
SYN
2.61+0.09(+3.53%)10:16 AMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.